Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Novo Nordisk, Sanofi, and Eli Lilly Lead in the $12 Billion U.S. Diabetes Market

Published: Monday, July 15, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
As diabetes rates reach alarming rates in the United States the market for diagnostics and treatment of the illness grows.

According to the latest statistics recorded by the American Diabetes Association, over 25 million children and adults in the United States were suffering from diabetes in 2011. Moreover, it is estimated that there are 79 million people who are prediabetic. People with prediabetes have an increased risk of becoming diabetic and are susceptible to the complications associated with the disease. However, if patients take action to better manage their blood glucose, they can delay or prevent diabetes from developing. The illness is the seventh leading cause of death in the U.S. and contributes to other maladies such as heart disease, stroke, blindness, amputations, and kidney failure.

According to the latest intelligence from iData Research, the market for diabetes monitoring, diagnosis, treatment, and drug delivery is valued at nearly $12 billion. With its success in treating both type 1 and type 2 diabetes, insulin represents the largest portion of the market. “This market is expected to maintain strong growth, and will be spurred by factors such as the number of diabetics, obesities, and alternative modes of delivery, such as insulin pens, pumps, and patches,” explains Dr. Kamran Zamanian, CEO of iData Research. “Units of insulin pens, for example, are expected to grow at double-digit rates, as newly diagnosed diabetics who are prescribed insulin are better informed of the conveniences of an insulin pen.” The dominant pen manufacturers are investing heavily in marketing, and the promotional backing is proving to be a very strong market driver.

Due to its great presence in both the insulin and insulin pen market in the U.S., Novo Nordisk is the market leader, dominating close to a quarter of the total market with products such as the NovoLog® and Novolin®R insulin products, and FlexPen®, NovoPen®, and NovoLet® insulin pens. Sanofi and Eli Lilly occupy the second and third places in the total market, respectively, competing with Novo Nordisk in the insulin and insulin pen markets. Lifescan and Roche Diagnostics are also large players, working primarily in the diabetes diagnostics sector. Lifescan is very involved in the diabetes community and is working to improve patient education and patient quality of life through development of new drugs, supporting legislation and healthcare reform to benefit people with diabetes. Roche Diagnostics is focused on innovation and forward-thinking solutions for healthcare. Their comprehensive portfolio includes products for reference labs, hospital labs, blood banks and specialty testing.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos